Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01535664 · ClinicalTrials.gov registry record
An Open Label, Proof of Concept Study to Evaluate the Effects of Dalfampridine Withdrawal on Gait and Balance Parameters in Subjects With Multiple Sclerosis (MS)
A clinical trial, sponsored by Acorda Therapeutics.
- Completed
- Registry status
- 20
- Enrollment target
NCT01535664 is a clinical trial that has completed, run by Acorda Therapeutics. The registered enrollment target is 20 participants.
The verdict
NCT01535664 has completed, sponsored by Acorda Therapeutics.
- COMPLETED
- Registry status
- 20 participants
- Enrollment target
Study Summary
The purpose of this study is to determine changes on overall gait as well as in multiple gait and balance parameters after withdrawal of dalfampridine-ER 10mg in MS subjects who are receiving the medication consistently for at least two weeks prior to screening.
Interventions
- OTHER Withdrawal of dalfampridine-ER 10mg
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 20 participants |
| Start Date | 2012-01 |
| Est. Completion | 2012-06 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01535664
The ClinicalTrials.gov registry entry for NCT01535664 describes a study currently listed as completed, categorized as an unspecified phase. The registered enrollment target is 20 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Acorda Therapeutics, which has 36 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Withdrawal of dalfampridine-ER 10mg is the first listed.
NCT01535664 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01535664 about?
NCT01535664 is a clinical study titled "An Open Label, Proof of Concept Study to Evaluate the Effects of Dalfampridine Withdrawal on Gait and Balance Parameters in Subjects With Multiple Sclerosis (MS)". The purpose of this study is to determine changes on overall gait as well as in multiple gait and balance parameters after withdrawal of dalfampridine-ER 10mg in MS subjects who are receiving the medication consistently for at least two weeks prior to screening.
What is the current status of trial NCT01535664?
This trial is currently completed. The enrollment target is 20 participants. The study started on 2012-01. Estimated completion is 2012-06.
What interventions are being tested in trial NCT01535664?
The interventions under investigation include: Withdrawal of dalfampridine-ER 10mg (OTHER).
Who is sponsoring clinical trial NCT01535664?
This trial is sponsored by Acorda Therapeutics, which has 36 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.